HemoShear Achieves Significant Milestone in Development of Predictive Human Tumor Drug Discovery Platform

CHARLOTTESVILLE, Va., Oct. 9, 2014 /PRNewswire/ -- HemoShear today announced that it has completed the first phase of development of a novel cancer drug discovery platform that replicates human tumor biology and responds to clinically-relevant drug concentrations. Funded by a contract with the NCI, HemoShear is developing a series of tumor models that recreate a wide variety of cancers for discovery of new drugs.

Using their new platform, HemoShear was able to successfully replicate human therapeutic response to Cisplatin, a drug approved to treat non-small cell lung carcinomoa (NSCLC), at a therapeutically-relevant concentration.  Similarly, HemoShear evaluated two other drugs currently in clinical studies and confirmed a therapeutic response.

When evaluated in traditional cell culture systems and mouse studies, the same dose of Cisplatin does not show a response. HemoShear's findings reinforce the need to test cancer drug candidates under more human-relevant tumor conditions.

"Nearly 95% of all cancer drugs entering clinical trials fail because of toxicity or lack of efficacy.  A major contributor to this dismal failure rate can be attributed to the inability of traditional models to uncover the underlying disease biology and predict efficacy and safety of cancer drug candidates," said Brian Wamhoff, Ph.D., Vice President of R&D and Co-founder of HemoShear. "With our novel approach to recreating the tumor microenvironment, we have demonstrated a major step toward understanding human response to cancer drug treatments."

"Our next step in collaborating with the NCI is to develop models for other tumor types and validate the models with several FDA-approved drugs and combination therapies," Dr. Wamhoff added.

HemoShear's translational tissue systems apply physiological blood flow characteristics to human tissue to restore its in vivo biology, using material from HemoShear's biorepository and interpreting data with cutting edge computational analytics. In Phase I of the NCI-funded program, HemoShear demonstrated that NSCLC tumor structure, biology, and molecular signaling pathways are restored in the HemoShear platform.

"HemoShear's goal is to enter drug discovery collaborations with select pharmaceutical and biotechnology companies to identify novel therapeutic approaches. We believe that our best-in-class tumor systems will fundamentally improve success of these drug candidates when they enter the clinic and accelerate the time it takes to get to patients," said Vincent Aurentz, HemoShear's Chief Business Officer. "The results from this phase are very encouraging and allow us to engage potential partners in further development of the tumor microenvironment for specific programs where HemoShear can bring real value."

About HemoShear, the Human Disease Biology Company
HemoShear is a biotechnology company that is changing the way drugs are discovered and developed, departing from traditional and often misleading scientific methods in favor of translational tissue systems that accurately replicate human disease biology. HemoShear's transformational drug discovery platform integrates first-in-class human disease systems, a comprehensive BioRepository, molecular and clinical disease expertise, and cutting-edge computational biology. Together, they provide a unique and powerful lens to interpret biological mechanisms and human disease at a level not possible until now. HemoShear works in strategic collaboration with pharmaceutical and biotechnology companies to discover new drugs across a wide range of diseases. HemoShear's collaborations uncover new targets, elucidate previously unknown mechanisms, identify novel attributes of drugs, differentiate drug candidates, and predict efficacy and safety of drugs before entering the clinic. Through its pioneering science, HemoShear's mission is to profoundly impact human health. THINK HUMAN.

SOURCE HemoShear

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED